Pancreatic
A022106 (JIT)
Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)
EA2192
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
EAY191 – E4 (Suspended)
Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial (Suspended)
EAY191-E5 (JIT)
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
RAIN-3202 (JIT)
A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors
S2001
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
S2104 (JIT)
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
TP-CA-007
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology